Shandong Xinhua Pharmaceutical Company Limited

SHSC:719 Stock Report

Market Cap: HK$9.4b

Shandong Xinhua Pharmaceutical Management

Management criteria checks 4/4

Shandong Xinhua Pharmaceutical's CEO is Wenhui Xu, appointed in Sep 2022, has a tenure of 2.67 years. total yearly compensation is CN¥1.81M, comprised of 94.5% salary and 5.5% bonuses, including company stock and options. directly owns 0.05% of the company’s shares, worth HK$4.75M. The average tenure of the management team and the board of directors is 5.4 years and 4.4 years respectively.

Key information

Wenhui Xu

Chief executive officer

CN¥1.8m

Total compensation

CEO salary percentage94.54%
CEO tenure2.7yrs
CEO ownership0.05%
Management average tenure5.4yrs
Board average tenure4.4yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Wenhui Xu's remuneration changed compared to Shandong Xinhua Pharmaceutical's earnings?
DateTotal CompensationSalaryCompany Earnings
Mar 31 2025n/an/a

CN¥440m

Dec 31 2024CN¥2mCN¥2m

CN¥470m

Sep 30 2024n/an/a

CN¥449m

Jun 30 2024n/an/a

CN¥492m

Mar 31 2024n/an/a

CN¥487m

Dec 31 2023CN¥2mCN¥1m

CN¥497m

Sep 30 2023n/an/a

CN¥510m

Jun 30 2023n/an/a

CN¥486m

Mar 31 2023n/an/a

CN¥454m

Jan 01 2023n/an/a

CN¥411m

Sep 30 2022n/an/a

CN¥357m

Jun 30 2022n/an/a

CN¥343m

Mar 31 2022n/an/a

CN¥357m

Dec 31 2021CN¥1mn/a

CN¥349m

Sep 30 2021n/an/a

CN¥364m

Jun 30 2021n/an/a

CN¥353m

Mar 31 2021n/an/a

CN¥339m

Dec 31 2020CN¥829kn/a

CN¥325m

Compensation vs Market: Wenhui's total compensation ($USD250.91K) is below average for companies of similar size in the Hong Kong market ($USD480.00K).

Compensation vs Earnings: Wenhui's compensation has been consistent with company performance over the past year.

CEO

Wenhui Xu (47 yo)

2.7yrs
Tenure
CN¥1,808,111
Compensation

Mr. Wenhui Xu serves as Executive Director and General Manager of Shandong Xinhua Pharmaceutical Company Limited since October 27, 2022 and September 19, 2022 respectively. He served as the Deputy General...

Leadership Team

NamePositionTenureCompensationOwnership
Tongqing He
Executive Chairman4.4yrsCN¥1.90m0.058%
HK$ 5.4m
Wenhui Xu
GM & Executive Director2.7yrsCN¥1.81m0.050%
HK$ 4.8m
Ning Hou
CFO & Executive Director11.1yrsCN¥1.57m0.063%
HK$ 5.9m
Changsheng Wei
Deputy GM & Manager of the Administrative Personnel Departmentno dataCN¥1.57m0.035%
HK$ 3.3m
Xuesong Liu
Deputy General Manager2.7yrsCN¥1.57m0.013%
HK$ 1.2m
Changqiu Cao
Company Secretary27.8yrsCN¥453.90k0.029%
HK$ 2.7m
Zhonghui Zheng
Deputy General Manager8.2yrsCN¥1.57m0.042%
HK$ 4.0m
Zuxing Kou
Deputy General Manager2.7yrsCN¥1.58m0.011%
HK$ 1.0m
Xiaohong He
Head of Accounting Departmentno datano datano data
5.4yrs
Average Tenure
51yo
Average Age

Experienced Management: 719's management team is seasoned and experienced (5.4 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Tongqing He
Executive Chairman4.4yrsCN¥1.90m0.058%
HK$ 5.4m
Wenhui Xu
GM & Executive Director2.6yrsCN¥1.81m0.050%
HK$ 4.8m
Ning Hou
CFO & Executive Director2.6yrsCN¥1.57m0.063%
HK$ 5.9m
Zhichao Tao
Independent Supervisor22.9yrsCN¥30.00kno data
Lie Xu
Non-Executive Director14.9yrsCN¥1.59m0.058%
HK$ 5.4m
Yanhua Hu
Employee Supervisor13.8yrsCN¥57.00kno data
Guangcheng Pan
Independent Non-Executive Director4.4yrsCN¥100.00kno data
Chengtong Liu
Chairman of Supervisory Committee4.4yrsno datano data
Jianwei Zhu
Independent Non-Executive Director4.4yrsCN¥100.00kno data
Peixue Ling
Independent Non-Executive Director2.6yrsCN¥100.00kno data
Chengyong Zhang
Non-Independent Director1.4yrsno datano data
Jingjing Zhang
Independent Non-Executive Director1.4yrsCN¥100.00kno data
4.4yrs
Average Tenure
52.5yo
Average Age

Experienced Board: 719's board of directors are considered experienced (4.4 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/22 19:43
End of Day Share Price 2025/05/22 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Shandong Xinhua Pharmaceutical Company Limited is covered by 3 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ming LiIndustrial Securities Co. Ltd.
Laurence TamMorgan Stanley
Guohe FanPhillip Securities (HK)